Collection of Blood Specimens for Circulating Tumor Cell Analysis

N/ACompletedNCT01943500

Viatar LLC14 enrolled

Overview

Objective: To test the sensitivity of a proprietary novel filtration device designed to capture and concentrate circulating tumor cells (CTCs).

Study Type

OBSERVATIONAL

Enrollment

Conditions

Breast Cancer Prostate Cancer Colorectal Cancer

Eligibility

Sex: ALLMin age: 18 YearsHealthy volunteers:

Medical Language ↔ Plain English

Inclusion Criteria: * Age \> 18 years of age * Written informed consent obtained * Confirmed diagnosis of stage 2-4 breast, prostate, or colorectal cancer, (OR) no prior history of cancer * Stage 2-4 treatment naive, metastatic, secondary, and recurrent cancer patients * Able to undergo blood collection prior to initiation of chemotherapy treatment, (OR) able to provide blood sample if subject is a non-cancer control subject Exclusion Criteria: * Patients unable to understand the research protocol and/or provide informed consent. * Patients with known immunodeficiency, or pregnancy.

Locations (1)

Commonwealth Hematology-Oncology, P.C.

Lawrence, Massachusetts, United States

Outcomes

Primary Outcomes

The number of circulating tumor cells (CTCs) per milliliter of whole blood. Reported unit of measure will be the number of CTCs/milliliter.

Blood samples will be collected from study subjects and analyzed for the number of circulating tumor cells (CTCs) within 96 hours of blood collection.

Time frame: Analysis will be performed within 96 hours following blood sample collection

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.